Table 4

Major adverse outcomes during follow-up

N (%)RepairReplacement
Secondary outcomes111 (28.0)16 (30.8)
 Death88 (22.2)13 (25.0)
 Tricuspid valve reoperation14 (3.5)*1 (1.9)*
 Readmission due to CHF22 (5.5)4 (7.7)
Other adverse outcomes62 (15.6)5 (9.6)
 Thromboembolic events18 (4.5)0
 Anticoagulation-related bleeding37 (9.3)4 (7.7)
 Other cardiac reoperation12 (3.0)1 (1.9)
 Infective endocarditis8 (2.0)0
All clinical endpoints148 (37.3)20 (38.5)
  • *Each includes one case of heart transplantation.

  • CHF, congestive heart failure.